Key result
ADAMTS16 promotes renal fibrosis by interacting with LAP-TGF-β and activating the TGF-β/Smad signaling axis, highlighting its potential as a therapeutic target for chronic kidney disease.
Why the study?
Renal fibrosis is the primary pathological basis of CKD progressing to ESRD, but effective treatments, drug targets, and diagnostic biomarkers are lacking.
ADAMTS16 is identified as a novel regulatory factor in renal fibrosis that activates TGF-β/Smad signaling, suggesting it may be a potential therapeutic target for chronic kidney disease.
May support ADAMTS16 as a fibrosis biomarker or target; hypothesis-generating for CKD until validated.
Chronic Kidney Disease (CKD) has emerged as a global public health concern, with its primary pathological basis being Renal Fibrosis (RF), crucial to halt its progression to End-Stage Renal Disease (ESRD). However, effective treatment options are currently lacking. Therefore, exploring the mechanisms of RF, identifying drug targets and diagnostic biomarkers are important. In this study, we identified ADAMTS16 as a newly expressed regulatory factor highly expressed in renal fibrosis tissue. ADAMTS16 interacts with latency-associated peptide (LAP)-transforming growth factor (TGF)-β, leading to the activation of TGF-β. Loss of ADAMTS16 expression effectively reduces TGF-β-dependent transcription activity. Furthermore, the use of RRFR tetrapeptide derived from ADAMTS16 can activate the TGF-β/Smad signaling axis, promoting RF. In summary, ADAMTS16 is induced in the progression of CKD, interacting with LAP-TGF-β and potentially activating SMAD2/3. Therefore, targeting ADAMTS16 may serve as a crucial new strategy to alleviate RF and treat CKD patients.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2024) studied Chronic Kidney Disease and Renal Fibrosis. ADAMTS16 was evaluated on TGF-β/Smad signaling activation and renal fibrosis. ADAMTS16 promotes renal fibrosis by interacting with LAP-TGF-β and activating the TGF-β/Smad signaling axis, highlighting its potential as a therapeutic target for chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: